Author

Xiaoyue Mou

Observed name: Xiao-Yue Mou

Institution: Taizhou First People's Hospital

Observed institution: Taizhou First People's Hospital

ORCID: 0000-0002-3961-8954

Observed ORCID: 0000-0002-3961-8954

OpenAlex ID: A5015747809

The efficacy and safety of TNF inhibitor (golimumab) as salvage treatment in patients with refractory noninfectious uveitis

2022 · Yi Jin, Shanshan Lu, et al. · Inflammopharmacology · 10

PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis

2022 · Qian Zhang, Du Jin, et al. · Journal of Clinical Laboratory Analysis · 7

RETRACTED: A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients

2021 · Jin-Tao Guan, Wei-Jie Wang, et al. · Therapeutic Advances in Chronic Disease · 6

Serum HDAC4 level in rheumatoid arthritis: Longitudinal change during treatment and correlation with clinical outcomes

2022 · Xiaoyue Mou, Yi Jin, et al. · Journal of Clinical Laboratory Analysis · 2

Granulocyte-macrophage colony-stimulating factor (GM-CSF) antibodies treatment for COVID-19 patients: a meta-analysis

2022 · Jin-Tao Guan, Wei-Jie Wang, et al. · medRxiv · 1

Real-world effectiveness and safety of firsekibart versus compound betamethasone in frequent gout flares: a multicenter retrospective study

2026 · Mengjie Chen, Xiaoyue Mou, et al. · Clinical Rheumatology

The Clinical Study of the Risk Factors of Type 2 Diabetes Mellitus with Vascular Lesions of Lower Extremities

2011 · Xiaoyue Mou · China Modern Doctor

Works count: 7

Citation count: 26

H-index: 3

I10-index: 1